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Objective: To evaluate the features and the predictors of “very late” recurrences after
surgery for localized renal cell carcinoma.
Methods: Since 1983, an institutional database with data of more than 2300
consecutive patients treated for renal cancer has been prospectively maintained.
Patients N0/NxM0 followed for a minimum of 10 years without recurrences were
retrieved. The site, time and treatment of recurrences observed afterwards were
recorded, and the predictors were investigated by Cox regression analysis.
Results: A total of 554 patients (231 women, 323 men; age 59.3  11.6 years)
followed for a mean/median time of 15.1/13.6 years (range 10.0–34.1 years) were
analyzed. A recurrence was observed in 26 patients (4.6%) after a mean/median interval
of 13.3/12.3 years (range 10.5–30.2 years). The pathological stage 2/3 was the only
independent predictor of recurrence (P = 0.003), and it was related also to the latency
of recurrence (mean/median latency 15.4/14.0, 11.4/10.8 and 12.5/12.0 years,
respectively, for stage 1, 2 and 3; P < 0.005 for stage 1 vs stage 2 or 3). The
contralateral kidney was the most frequent site of relapse in patients with stage pT1,
whereas multiple sites were more frequent for stage pT2 and pT3.
Conclusions: The risk of a “very late” recurrence of renal cancer is approximately 5%,
and it depends on the pathological stage. For stage pT1, the kidney/s should be surveilled
for indefinite time, preferably by ultrasound to reduce the X-ray exposition; for stage pT2
and pT3, the abdomen and the lungs should be monitored, by computed tomography
scan during the first years, and then by abdominal ultrasound and chest X-ray.
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Introduction
Relapses after surgery for renal cancer account for 20–40% of cases without metastasis at
diagnosis.1,2 For patients who experienced relapse, curative options are very limited, even
after the introduction of targeted therapies, which are effective in 20–40% of cases, but able
to reach a complete and durable response in a minimal (2%) proportion.3 Therefore, the early
detection of a recurrence is crucial, because surgical removal can lead to the regression of the
disease in a significant proportion of patients and in a minority of them be truly curative.4
The advantages of intensive follow up must be balanced by the economic costs of instrumen-
tation and operators, as well as the biological burden related to the exposure to ionizing radia-
tion. Recurrences can occur in multiple sites, mainly in the lungs, adrenal glands, bones and
kidneys, but also in various atypical sites,5,6 making the extent and the frequency of a CT
scan very difficult to define.7,8
Thus, the duration of follow up is a matter of interest, especially for the patients who remain
free from recurrences for many years, as they benefit from a long-term life expectancy.
Many retrospective studies defined some risk groups based on post operative or preopera-
tive features to rationalize follow-up schedules.9,10 However, these studies provided mean/me-
dian follow-up duration of approximately 5 years, and their results should be applied
exclusively for the prediction of recurrences during this time range. Also, the European Asso-
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guidelines suggest well-defined strategies only for the first
5 years after surgery, but afterwards recommendations are
generic or not reported at all.11,12
Nevertheless, recurrences could also occur after a very
long latency, up to more than 40 years,13,14 and therefore
clinicians are generally reluctant to suspend controls. Con-
temporary data on late recurrences have been reported by
very few studies and from tertiary institutions or collaborative
databases, which investigated follow up after the first 5 years
of negative controls,15–18 but, to our knowledge, only one
multicenter Japanese study assessed the outcome of “very
late” recurrences; that is, those that occurred after 10 years of
negative controls.19 Therefore, the evidence to trigger follow
up after 10 years without relapses is very weak or empiric.
The aim of the present study was to evaluate the features,
risk factors and clinical outcome of “very late” recurrences
observed in a single-center large cohort followed for a mini-
mum of 10 years of negative controls.
Methods
Since 1983, the clinical, surgical, pathological and follow-up
data of more than 2300 patients submitted to surgery for a
renal mass at our institution have been stored in a prospec-
tively maintained database. For the present study, in lieu of a
formal approval from the ethical committee, the principles of
the Declaration of Helsinki were followed.
The data of patients operated up to the year 2004 for a
non-metastatic (N0/Nx M0) renal carcinoma were retrieved
from this database, so that a minimum follow-up time of
10 years could be warranted; in particular, the cases in which
no recurrences were observed during their first 10 years were
recruited.
During the study period, both partial and radical nephrec-
tomy were carried out by open surgery according to current
guidelines.
A single expert uropathologist (RT) reviewed all the histo-
logical specimens. TNM staging was updated to the 2009
version; histological subtype and grading were assigned
according to the recommendations of the World Health Orga-
nization 2004 classification and International Society of
Uropathologists.20,21
All the patients were followed at a dedicated office, for an
unrestricted timespan, applying a single schedule of controls
regardless of the clinical and pathological baseline features of
each case. In particular, at each visit patients were submitted
to a physical examination, and provided blood and urine
tests, and a chest and abdominal study at an interval of
6 months for the first 2 years, then yearly; chest X-ray along
with abdominal ultrasonography were alternated to thorax
and abdominal computer tomography, unless the use of med-
ium contrast was contraindicated. Periodically, the records of
patients who missed their planned control were updated by
telephone interview or hospital database consultation.
The site, time and treatment of recurrences were recorded.
At the diagnosis of a recurrence, a whole body restaging was
carried out. A histological diagnosis of the metastasis was car-
ried out in all cases; surgical treatment of the relapse was indi-
cated in all the cases with an isolated recurrence, when
technically feasible, whereas a medical therapy was carried out
in cases with diffuse metastasis, with interleukin-2 or inter-
feron before the year 2005, with target therapy afterwards.
Statistical analysis
Categorical variables were compared by Fisher’s exact test or
v2-test, and continuous variables by t-test or U-test, as appro-
priate.
A Cox regression model was applied to investigate dis-
ease-free survival and to find predictors of recurrence; the
Kaplan–Meier method was used to estimate differences in
survival among groups of patients; disease-free survival was
considered as the interval from the date of surgery to relapse
or the last follow up available. All P-values were two-tailed
and considered as significant if <0.05 (Software SPSS v.13.0;
IBM, Armonk, NY, USA).
Results
The study recruited 554 patients with a non-metastatic renal
carcinoma (231 women, 323 men, mean age 59.3 
11.6 years) followed for a mean/median time of 15.1/
13.6 years (range 10.0–34.1 years). The baseline features of
the cohort are summarized in Table 1. At the last available
follow up, 453 patients (81.7%) were alive without evidence
of recurrence, nine (1.6%) with a progression, 15 (2.7%) died
as a result of renal cancer and 77 (13.9%) died as a result of
causes unrelated to the renal cancer. Cancer-specific survival
was 98.2% and 96.0% at 15 and 20 years, respectively,
whereas other-cause survival was 88.4% and 75.8%.
An event of progression was observed in 26 patients
(4.6%) after a mean and median interval of 13.3 and
12.3 years (range 10.5–30.2 years) from surgery.
At univariate analysis, tumor diameter and pathological T
were related to the risk of recurrence; whereas at multivari-
able analysis, only the pathological T retained this relationship
(P = 0.003, Table 2). Patients with stage pT1, pT2 and pT3
were followed for a mean/median time of 15.0/13.9 years,
15.4/15.0 years and 15.3/13.4 years (P not significant); the
estimation of disease-free survival with the Kaplan–Meier
equation (Fig. 1) confirmed a significant difference between
pT1 versus pT2 and pT3 grouped (log–rank test, P = 0.002).
The mean/median latency of recurrence was 15.4/14.0 years,
11.4/10.8 years and 12.5/12.0 years (stage 1 vs stage 2,
P < 0.001; stage 1 vs stage 3, P = 0.047).
In Table 3, the site, latency and treatment of recurrences,
and the survival from the time of recurrence are reported.
The contralateral kidney was the most frequent site of relapse
in pT1 patients (55.6% of the relapses); whereas for patients
with pT3, relapses in multiple sites were more frequently
observed (45.5% of the relapses vs 16.5% and 22.2% in stage
2 and 1, respectively).
Discussion
The present study investigated the issue of “very late”
relapses of renal carcinoma; that is, the relapses that occurred
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after at least 10 years of uneventful follow up. With this aim,
a large cohort of surgical patients was analyzed, treated at a
tertiary academic institution and followed through a homoge-
neous schedule of control that was not tailored to the baseline
features of the patients.
There are several important findings to remark on.
First, the risk that a renal carcinoma N0/NxM0 at diagnosis
further develops a very late progression is not negligible,
being approximately 5%, and depends on the stage of the
tumor. In particular, for patients with larger – pT2 – and
more advanced tumors – pT3 – the risk is similar, 11% and
9%, whereas for patients with pT1 it is significantly lower,
close to 2%.
Second, the patients with a stage pT1 frequently showed
an isolated recurrence in the contralateral kidney, occurring
after a very long interval. Given this latency from the first
operation and the good prognosis after salvage surgery, it
should be questioned if these are true relapses or newborn
tumors: histological subtype was concordant in all the cases
and grading in six out of eight, supporting the hypothesis of
a recurrence, but only a comparison of the chromosomal or
genetic pattern of alterations of the two tumors could ascer-
tain this hypothesis. Also, the patients with a stage pT2 expe-
rienced more frequently isolated recurrences, not in the
kidney, but interestingly in sites that are not usually colo-
nized by renal cancer, such as the thyroid and pancreas, con-
firming that these late recurrences are typical of a disease
with a particular biological behavior.22,23 Finally, patients
with stage pT3 had more frequent relapses in multiple sites,
generally diagnosed during the years 10–13.
Third, it can be stated that a schedule with a yearly check
of the abdomen and chest allows an early diagnosis of the
recurrence – that is, a recurrence still amenable with surgical
therapy – in two thirds of cases. At the same time, controls
were not intense enough for pT3 patients, as they had a mul-
tiple recurrence in approximately 50% of cases. It is notewor-
thy that the median survival from the recurrence of the
patients of this study amenable to metastasectomy was
5.1 years versus 1.3 years for the cases in which surgery was
not feasible. Such a difference in survival supports the use of
an extended and tailored follow up. Indeed, as these patients
have renal cancer without an aggressive behavior, and given
that 10 years passed without recurrences, it is reasonable to
point out that the differences in survival can be attributed to
the punctuality of diagnosis and treatment.
The literature that specifically investigates the issue of
relapses beyond 10 years is very poor, probably because an
accurate collection of data on late outcomes is possible only
with a dedicated institutional office, which was established at
our center in the 1980s. Otherwise, at that time patients are
poorly motivated, and tend to shift from a systematic follow
up to a regimen more similar to observation.
Miyao et al. published the only study, to our knowledge,
on very late recurrences: it analyzed the data of 470 patients
followed for at least 10 years, finding that only lymphnodal
invasion – and not the pathological stage – was a predictor
of recurrence.19 Some comments should be made to com-
pare the two studies. First, we did not include N+ cases,
because it is quite extraordinary that such patients have not
experienced any relapse in the first years of controls – in
our cohort, there were just six patients N+ followed for
more than 10 years with no relapses. Thus, the clinical util-
ity of a stratification on the lymphnodal status to determine
if long-term follow up is necessary is quite debatable.
Furthermore, the source of data is completely different: in
Miyao’s study, 13 centers with heterogeneous follow-up reg-
imens were involved, but in the present study there was a
Table 1 Baseline features of the cohort
Feature Value
Type of surgery, no. patients (%)
Partial nephrectomy 131 (23.7)
Radical nephrectomy 423 (76.3)

















Clinical stage, no. patients (%)
1–2 422/554
3–4 132/554
















Lymphonodal status, no. patients (%)
Nx 389 (71.5)
N0 155 (27.5)





Histological subtype, no. patients (%)
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single institution that applied the same schedule of controls
to all the patients. Third, the features of patients in Miyao’s
study were largely different from the present patients and
the contemporary scenario of renal cancer in Western
countries, as <2% were submitted to partial nephrectomy
and 55% received some adjuvant therapy.
A few more studies focused their attention on the recur-
rences that occurred after 5 years of controls and, even within
given limits, their results might be compared with ours.
Uchida et al. on a cohort of 239 cases did not find any factor
related to late recurrence.15 Brookman-May et al., from a
very large (>5000 patients) international multicenter dataset,
concluded that the risk of late recurrence is related to grad-
ing, lymphovascular invasion and pT stage >1, confirming
the present findings.16 Also, Kim et al. in a single center
study, on a large cohort (>1400 patients), confirmed that the
stage is a strong predictor of late recurrence.18
In conclusion, the risk of a “very late” recurrence in non-
metastatic renal cancer patients is approximately 5%, and
the pathological stage is the main predictor, being related
also to the latency from surgery. On the basis of the patterns
of recurrence observed after 10 years of uneventful follow
up, it is possible to give the following suggestions: for stage
pT1, the kidney/s should be surveilled for an indefinite time-
span, preferably by ultrasound to reduce the X-ray exposi-
tion; for stage pT2 and pT3, the whole abdomen and the
lung should be monitored, by CT scan in the first years
when the risk is higher, afterwards by abdominal ultrasound
and chest X-ray.
Table 2 Univariate and multivariable Cox regression analysis of progression-free survival (only statistically significant results are reported)
Feature
Univariate analysis
RR (95% CI) P
Multivariable analysis
RR (95% CI) P
Age (continuous, years) 1.003 (0.998–1.015) 0.459
Male 1.287 (0.971–1.341) 0.132
Symptoms 1.416 (0.891–2.321) 0.324
Laterality (uni- vs bilateral) 1.121 (0.732–3.123) 0.519
Clinical stage (intra vs extracapsular) 1.988 (0.873–2.512) 0.731
Type of surgery (partial vs radical nephrectomy) 2.221 (0.912–4.320) 0.115
Histological subtype (clear cell vs others) 1.561 (0.787–3.123) 0.667
Tumor diameter (continuous, cm) 1.198 (1.077–1.333) 0.001 1.231 (0.997–1.455) 0.216
Pathological stage 0.003 0.003
1 Referent Referent
2 3.544 (1.182–10.626) 0.008 6.423 (1.414–29.183) 0.016
3 3.580 (1.478–8.674) 0.002 6.967 (2.146–22.618) 0.001






















Fig. 1 Curves of estimated disease-free survival of patients with renal can-
cer pT1 versus pT2/pT3 showing a statistically significant difference (log–rank
test, P = 0.002; the scale of the y-axis starts from 0.80 to render the differ-
ence between curves more evident).
Table 3 Latency, treatment, outcome and distribution in each pathological stage of the sites of relapses





Contralateral kidney 8 12.9 Surgery 8 6.7 5/8 (62.5) – 3/8 (37.5)
Lung 5 11.1 Surgery 3, medical therapy 2 4.8 1/5 (20.0) 2/5 (40.0) 2/5 (40.0)
Pancreas 4 12.0 Surgery 4 2.7 1/4 (25.0) 2/4 (50.0) 1/4 (25.0)
Thyroid 1 13.5 Surgery 1 3.2 – 1/1 (100.0) –
Multiple† 8 12.0 Medical therapy 8 1.5 2/8 (25.0) 1/8 (12.5) 5/8 (62.5)
†Kidney, lung and bone – 2 patients; lung and bone – 3 patients; lung and renal fossa – 2 patients; lung, liver and bone – 1 patient.
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Editorial Comment
Editorial Comment to Features, risk factors and clinical outcome of “very late”
recurrences after surgery for localized renal carcinoma: A retrospective evaluation of
a cohort with a minimum of 10 years of follow up
Late recurrence has been considered to be one of the unique
behaviors of renal cell carcinoma (RCC). The present study
was carried out to evaluate the features and risk factors of
“very late” recurrences in RCC patients followed for a mini-
mum 10 years of negative controls after curative surgery.1 Of
554 patients treated in an Italian single center, “very late”
recurrence was observed in 26 patients, and the pathological
stage was shown to be the main predictor for late recurrence.
Although the contralateral kidney was the most frequent site
of recurrence in pT1 patients, multiple sites were more fre-
quently observed in pT3 patients. The authors recommended
a longer follow-up schedule for RCC patients based on the
initial pathological stage of primary tumor.
As mentioned by the authors, the articles on “very late”
recurrence of curatively resected RCC are rare. However,
“very late” recurrences have been well-known in Japan, and
are considered to be unremarkable events in RCC patients.
Onishi et al. evaluated the clinical outcomes of 50 patients
who survived for more than 10 years after nephrectomy car-
ried out at the Jikei University Hospital and affiliated institu-
tions.2 Of these, recurrences were detected in four patients
(8%) 10 years postoperatively. Miyao et al. also evaluated
clinical features and outcomes of late recurrences observed in
the Japanese multicenter collaborative database.3 The fre-
quency of “very late” recurrences was 6.4%, almost equal to
the rate observed in the present study (4.6%).1,3 Thus, “very
late” recurrences might be relatively rare events, but have
been shown to occur regardless of race. Furthermore, recur-
rences were detected as a solitary metastasis in 69% of 26
patients with “very late” recurrences in the present study
(contralateral kidney in eight, lung in five, pancreas in four
and thyroid in one).1 Miyao’s study reported similar results
(87% of all recurrent patients; lung in 16, contralateral kidney
in 11 etc.).3 To these patients, metastasectomy is frequently
recommended. When the lesion is relatively localized, metas-
tasectomy might also contribute to an improved prognosis.4
Naito et al. analyzed the prognosis of 559 Japanese meta-
static RCC patients who had undergone metastasectomy, and
reported that their prognosis was excellent, with a median
overall survival of approximately 8 years.5 In contrast, if
early detection could not be carried out, disease progression
occurs even in patients followed for a minimum 10 years of
negative controls after curative surgery, and a chance of cura-
tive metastatectomy would be missed in these patients. There-
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